PUBLISHER: The Business Research Company | PRODUCT CODE: 2057559
PUBLISHER: The Business Research Company | PRODUCT CODE: 2057559
Peptide therapeutics contract API manufacturing refers to outsourced, specialized services that produce peptide-based active pharmaceutical ingredients for drug developers and pharmaceutical companies. These services typically include solid-phase or liquid-phase peptide synthesis, purification, characterization, scale-up, and GMP-compliant manufacturing to meet regulatory requirements for clinical and commercial use. The primary purpose of contract peptide API manufacturing is to enable reliable, high-quality, and scalable production of peptide drugs without requiring in-house manufacturing infrastructure.
The peptide therapeutics contract API manufacturing market consists of sales, by entities (organizations, sole traders, or partnerships), of peptide therapeutics contract API manufacturing that used by pharmaceutical companies during drug development and commercial production. During the preclinical and clinical phases, peptide APIs are used for early research, toxicology testing, and clinical trial supplies.
The global peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market grew from $1,967.8 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 7.0%.
Expansion Of Clinical Trials And Robust Therapeutic Pipeline
During the historic period, the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market was significantly driven by the expansion of clinical trials and robust therapeutic pipeline. As pharmaceutical and biotechnology companies advanced a growing number of peptide candidates into preclinical and clinical evaluation, the need for consistent, GMP-compliant peptide APIs intensified across multiple trial phases. Internal manufacturing capabilities were often insufficient to support parallel programs, varying batch sizes, and frequent process adjustments required during clinical progression. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the total number of clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023. Therefore, the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market was significantly driven by the expansion of clinical trials and robust therapeutic pipeline.
Digitalization, Cloud, Big Data And Cybersecurity
Digitalization is reshaping operational and quality management frameworks across the peptide therapeutics contract API manufacturing landscape. Cloud-based platforms and big data analytics are being deployed to integrate R&D data, manufacturing records, and quality documentation across global facilities. As manufacturers increasingly handle proprietary molecular sequences and sensitive clinical data, cybersecurity has become a strategic priority, with robust digital safeguards implemented to protect intellectual property, ensure data integrity, and meet stringent regulatory expectations. For instance, in May 2025, Lonza, a Switzerland-based global contract development and manufacturing organization, announced the launch of its new Design2Optimize platform aimed at streamlining active pharmaceutical ingredient (API) process development by leveraging a model-based design of experiments (DoE) and predictive modelling to reduce the number of physical experiments required, enhance process optimization, and accelerate timelines for peptide API process development and manufacturing in the peptide therapeutics contract active pharmaceutical ingredient market.
The global peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is concentrated, with a large players dominating across major regions. The top 10 competitors in the market made up 47.8% of the total market in 2024.
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global peptide therapeutics contract API manufacturing market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for peptide therapeutics contract API manufacturing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide therapeutics contract API manufacturing market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider peptide therapeutics contract API manufacturing market; and compares it with other markets.
Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report